search
Back to results

Glucagon Like Peptides Receptors Expression in the Stomach of Diabetes Type 2 (GLP)

Primary Purpose

Diabetes Mellitus Type 2

Status
Unknown status
Phase
Phase 4
Locations
Israel
Study Type
Interventional
Intervention
GLP receptors expression
ESOPHAGOGASTRODUODENOSCOPY
Sponsored by
Assaf-Harofeh Medical Center
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Diabetes Mellitus Type 2 focused on measuring PATIENTS WITH DIABETES MELLITUS TYPE 2, UNDERGO UPPER ENDOSCOPY, BIOPSIES FOR GLP RECEPTORS EXPRESSION, PCR ANALYSIS

Eligibility Criteria

18 Years - 70 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • 20 diabetes type 2 patients with symptoms that need upper endoscopy will be included in the study and 20 controls aged 18-70 years

Exclusion Criteria:

  • Patients with neurological disease will be excluded

Sites / Locations

  • Assaf Harofeh Medical Center

Outcomes

Primary Outcome Measures

Secondary Outcome Measures

Full Information

First Posted
May 13, 2007
Last Updated
May 14, 2007
Sponsor
Assaf-Harofeh Medical Center
search

1. Study Identification

Unique Protocol Identification Number
NCT00473733
Brief Title
Glucagon Like Peptides Receptors Expression in the Stomach of Diabetes Type 2
Acronym
GLP
Study Type
Interventional

2. Study Status

Record Verification Date
April 2007
Overall Recruitment Status
Unknown status
Study Start Date
undefined (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
undefined (undefined)

3. Sponsor/Collaborators

Name of the Sponsor
Assaf-Harofeh Medical Center

4. Oversight

5. Study Description

Brief Summary
Glucagon like peptides receptors expression in the stomach of diabetes type 2 Glucagon like peptides (GLP-1, GLP-2), are hormones secreted by L cells located along the gastrointestinal tract. These hormones are secreted after meals and have some roles in regulating the digestion process, absorption, and sending signals to the brain that regulate food consumption. GLP peptides affect peripheral targets and have an important homeostatic role. GLP-1 decreases the circulatory glucose level and GLP-2 has trophic effects which enable adequate intestine growth. We aimed in our study to investigate the GLP-1 and GLP-2 receptor expression in different zones of the stomach in diabetes type 2 patients. If there are differences, it might explain the pathological gastric emptying in these patients. Understanding the function of these peptides may lead to new therapeutic options for diabetic patients with delayed gastric emptying. Methods: 20 diabetes type 2 patients with symptoms that need upper endoscopy will be included in the study and 20 controls aged 18-70 years. Patients with neurological disease will be excluded. During esophagogastroduodenoscopy 3 biopsies will be taken from the antrum, corpus and cardia. The biopsies will be stored in -70. After RNA extraction the GLP receptors expression will established by real time PCR method. Patients with different expression compared to control will undergo isotopic scan for gastric emptying.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes Mellitus Type 2
Keywords
PATIENTS WITH DIABETES MELLITUS TYPE 2, UNDERGO UPPER ENDOSCOPY, BIOPSIES FOR GLP RECEPTORS EXPRESSION, PCR ANALYSIS

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Phase 4
Interventional Study Model
Crossover Assignment
Masking
None (Open Label)
Allocation
Non-Randomized

8. Arms, Groups, and Interventions

Intervention Type
Procedure
Intervention Name(s)
GLP receptors expression
Intervention Type
Procedure
Intervention Name(s)
ESOPHAGOGASTRODUODENOSCOPY

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: 20 diabetes type 2 patients with symptoms that need upper endoscopy will be included in the study and 20 controls aged 18-70 years Exclusion Criteria: Patients with neurological disease will be excluded
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Efrat Broide, MD
Phone
972-8-9779722
Email
efibroide@yahoo.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Efrat Broide, MD
Organizational Affiliation
Ethic committee of Asaaf Harofeh Medical Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
Assaf Harofeh Medical Center
City
Zerifin
ZIP/Postal Code
70300
Country
Israel
Facility Contact:
First Name & Middle Initial & Last Name & Degree
eFRAT Broide, MD
Phone
972-8-9779722
Email
efibroide@yahoo.com
First Name & Middle Initial & Last Name & Degree
Efrat Broide, MD

12. IPD Sharing Statement

Learn more about this trial

Glucagon Like Peptides Receptors Expression in the Stomach of Diabetes Type 2

We'll reach out to this number within 24 hrs